FIELD: medicine.
SUBSTANCE: prolonged release pharmaceutical preparative form contains approximately 35-80% of ranolasine, a pH-independent binding agent and one or more pharmaceutically acceptable excipient. The pharmaceutical preparative form of ranolasine contains hydroxypropylmethyl cellulose as said pH-independent binding agent. The pharmaceutically acceptable excipients represent magnesium stearate and microcrystalline cellulose. The preparative form of ranolasine is used for treatment of cardiovascular diseases.
EFFECT: preparative form of ranolasine under the invention provides effective levels of ranolasine in blood plasma within 12 hours.
15 cl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATMENT OF CARDIOVASCULAR DISEASES | 1999 |
|
RU2207856C2 |
| PHARMACEUTICAL COMPOSITION OF SLOW RELEASE, CONTAINING APLINDOR AND ITS DERIVATIVES | 2004 |
|
RU2376988C2 |
| TABLETS OF TAMSULOSIN WITH MODIFIED RELEASE | 2002 |
|
RU2335280C2 |
| PHARMACEUTICAL COMPOSITION AT DELAYED RELEASE OF PHARMACEUTICALLY ACTIVE SUBSTANCE AND METHOD FOR RELEASING PHARMACEUTICALLY ACTIVE SUBSTANCE | 1999 |
|
RU2259826C2 |
| SOLID TABLETS AND CAPSULES OF MODIFIED RELEASE OF BENZONATATE | 2014 |
|
RU2673239C2 |
| METHOD OF DIABETES TREATMENT | 2007 |
|
RU2442585C2 |
| RANOLAZINE PREPARATIONS WITH PROLONGED EFFECT | 1999 |
|
RU2214233C2 |
| CLOZAPINE TABLETS WITH DELAYED RELEASE AND METHOD OF OBTAINING THEREOF | 2015 |
|
RU2624229C2 |
| TAMZULOSIN TABLETS | 2002 |
|
RU2311903C2 |
| PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF LEVODOPA PRODRUG AND METHODS OF USING | 2010 |
|
RU2537137C2 |
